Could a faster insulin improve blood sugar control in teens with type 1 diabetes?

NCT ID NCT06948760

Completed Disease control Sponsor: Mark D. DeBoer, MD, MSc., MCR Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed trial tested whether a faster-acting insulin (Lyumjev) used with a special conversion factor in an automated insulin pump (Control-IQ) could improve blood sugar control in 11 adolescents with type 1 diabetes. Participants were randomly assigned to use Lyumjev with the new settings or their usual insulin (Humalog or Novolog) with optimized settings. The main goal was to see if the Lyumjev group spent more time in the target blood sugar range (70-180 mg/dL).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lyumjev insulin (ultra-rapid-acting insulin)
What this could lead to: If successful, this could help adolescents with type 1 diabetes achieve better blood sugar control using a faster-acting insulin in an automated pump.
What could go wrong: This was a very small trial (11 participants) with no phase designation, so results may not be generalizable. Faster insulin also carries a risk of hypoglycemia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

University of Virginia Center for Diabetes Technology

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.